Drug intelligence / Profile preview

PBX-CB-01

Development stage: Preclinical
Lead developer: PinotBio
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Parenteral

Overview

PBX-CB-01 is an antibody-drug conjugate (ADC) developed by Pinotbio using the PINOT-ADC platform. It is being investigated as an antineoplastic agent for the treatment of solid tumors. The precise mechanism of action and molecular target have not been publicly disclosed as of June 2025. As a typical ADC, it likely functions by targeting a specific antigen on tumor cells, delivering a cytotoxic payload directly to malignant cells to enhance efficacy and reduce systemic toxicity. The drug is currently in preclinical development with no orphan drug designation or regulatory approvals reported[1][2][3].

Brand names: PBX-CB-01PBX-CB01PBX-CB 01
Other names: PBX CB 01

Beyond the preview

Go deeper on PBX-CB-01.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PBX-CB-01.

Explore the full profile